MetaADEDB 2.0 @ LMMD
Ospemifene
(LUMKNAVTFCDUIE-VHXPQNKSSA-N)
Structure
SMILES
ClCC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCO)/c1ccccc1
Type(s)
Approved; Investigational
ATC code(s)
G03XC05
Molecular Formula:
C24H23ClO2
Molecular Weight:
378.891
Log P:
5.6457
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
1
TPSA:
29.46
CAS Number(s):
128607-22-7
Synonym(s)
1.
Ospemifene
2.
FC-1271a
3.
Osphena
4.
Z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol
External Link(s)
MeSHC119141
PubChem Compound3036505
ChEBI73275
CHEMBLCHEMBL2105395
DrugBankDB04938
DrugCentral4749
IUPHAR/BPS Guide to PHARMACOLOGY7349
KEGGdr:D08958
Therapeutic Target DatabaseD02CTS
ZINC1550766
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1HeadacheFAERS: 118US FAERS
2No adverse eventFAERS: 118US FAERS
3Vaginal DischargeFAERS: 65SIDER
US FAERS
4Drug ineffectiveFAERS: 50US FAERS
5NauseaFAERS: 45US FAERS
6DizzinessFAERS: 39US FAERS
7Therapeutic response unexpectedFAERS: 33US FAERS
8PruritusFAERS: 27US FAERS
9AlopeciaFAERS: 24US FAERS
10Drug prescribing errorFAERS: 24US FAERS
11HypersensitivityFAERS: 23US FAERS
12FatigueFAERS: 22US FAERS
13Night sweatsFAERS: 22US FAERS
14UrticariaFAERS: 21US FAERS
15Deep Vein ThrombosisFAERS: 19SIDER
US FAERS
16Abdominal discomfortFAERS: 18US FAERS
17PalpitationsFAERS: 18US FAERS
18Vulvovaginal burning sensationFAERS: 18US FAERS
19Breast tendernessFAERS: 16US FAERS
20Chest PainFAERS: 16US FAERS
21Vulvovaginal pruritusFAERS: 16US FAERS
22Abdominal PainFAERS: 15US FAERS
23ArthralgiaFAERS: 15US FAERS
24Feeling abnormalFAERS: 15US FAERS
25Unevaluable eventFAERS: 15US FAERS
26AnxietyFAERS: 14US FAERS
27DyspareuniaFAERS: 14US FAERS
28Inappropriate schedule of drug administrationFAERS: 14US FAERS
29Poor quality sleepFAERS: 14US FAERS
30Endometrial thickeningFAERS: 13US FAERS
31Therapy cessationFAERS: 13US FAERS
32Inability to afford medicationFAERS: 12US FAERS
33Mood swingsFAERS: 12US FAERS
34Product use in unapproved indicationFAERS: 12US FAERS
35Vulvovaginal discomfortFAERS: 12US FAERS
36MyalgiaFAERS: 11US FAERS
37Peripheral swellingFAERS: 11US FAERS
38ThrombosisFAERS: 11US FAERS
39Urinary tract infectionFAERS: 11US FAERS
40AstheniaFAERS: 10US FAERS
41Burning sensationFAERS: 10US FAERS
42Prescribed underdoseFAERS: 10US FAERS
43Cerebrovascular accidentFAERS: 9US FAERS
44PainFAERS: 9US FAERS
45Vulvovaginal drynessFAERS: 9US FAERS
46ChillsFAERS: 8US FAERS
47ConstipationFAERS: 8US FAERS
48DyspepsiaFAERS: 8US FAERS
49ErythemaFAERS: 8US FAERS
50Vulvovaginal painFAERS: 8US FAERS
51AcneFAERS: 7US FAERS
52MalaiseFAERS: 7US FAERS
53TremorFAERS: 7US FAERS
54Uterine PolypFAERS: 7US FAERS
55VomitingFAERS: 7US FAERS
56Vulvovaginal erythemaFAERS: 7US FAERS
57Vulvovaginal swellingFAERS: 7US FAERS
58Lip swellingFAERS: 6US FAERS
59Memory impairmentFAERS: 6US FAERS
60Pulmonary EmbolismFAERS: 6US FAERS
61VertigoFAERS: 6US FAERS
62Back PainFAERS: 5US FAERS
63Dry skinFAERS: 5US FAERS
64ArthritisFAERS: 4US FAERS
65Drug ineffective for unapproved indicationFAERS: 4US FAERS
66DysgeusiaFAERS: 4US FAERS
67Endometrial HyperplasiaFAERS: 4US FAERS
68Therapeutic response changedFAERS: 4US FAERS
69Accidental overdoseFAERS: 3US FAERS
70AmnesiaFAERS: 3US FAERS
71Bacterial VaginosisFAERS: 3US FAERS
72Coital bleedingFAERS: 3US FAERS
73CryingFAERS: 3US FAERS
74Depressed moodFAERS: 3US FAERS
75DisorientationFAERS: 3US FAERS
76Drug dose omissionFAERS: 3US FAERS
77DysuriaFAERS: 3US FAERS
78Emotional disorderFAERS: 3US FAERS
79Expired product administeredFAERS: 3US FAERS
80Genital erythemaFAERS: 3US FAERS
81Intentional product misuseFAERS: 3US FAERS
82Medication ErrorFAERS: 3US FAERS
83MetrorrhagiaFAERS: 3US FAERS
84NervousnessFAERS: 3US FAERS
85Oropharyngeal painFAERS: 3US FAERS
86Pelvic PainFAERS: 3US FAERS
87SomnolenceFAERS: 3US FAERS
88SwellingFAERS: 3US FAERS
89Throat irritationFAERS: 3US FAERS
90Visual ImpairmentFAERS: 3US FAERS
91Vulvovaginal mycotic infectionFAERS: 3US FAERS
92Wrong technique in product usage processFAERS: 3US FAERS
93Accidental exposure to productFAERS: 2US FAERS
94Adverse eventFAERS: 2US FAERS
95AnorgasmiaFAERS: 2US FAERS
96Bladder spasmFAERS: 2US FAERS
97Blood cholesterol increasedFAERS: 2US FAERS
98Bone painFAERS: 2US FAERS
99BronchitisFAERS: 2US FAERS
100Chest discomfortFAERS: 2US FAERS
101CystitisFAERS: 2US FAERS
102EczemaFAERS: 2US FAERS
103Endometrial disorderFAERS: 2US FAERS
104Endometrial hypertrophyFAERS: 2US FAERS
105EpistaxisFAERS: 2US FAERS
106Exertional headacheFAERS: 2US FAERS
107Exposure during breast feedingFAERS: 2US FAERS
108Flank PainFAERS: 2US FAERS
109FlatulenceFAERS: 2US FAERS
110Gastrointestinal PainFAERS: 2US FAERS
111Genital dischargeFAERS: 2SIDER
US FAERS
112HysterectomyFAERS: 2US FAERS
113Intentional product use issueFAERS: 2US FAERS
114Joint swellingFAERS: 2US FAERS
115LethargyFAERS: 2US FAERS
116Middle insomniaFAERS: 2US FAERS
117NasopharyngitisFAERS: 2US FAERS
118Neck PainFAERS: 2US FAERS
119Ocular discomfortFAERS: 2US FAERS
120Pain of skinFAERS: 2US FAERS
121Product package associated injuryFAERS: 2US FAERS
122Pulmonary thrombosisFAERS: 2US FAERS
123TachycardiaFAERS: 2US FAERS
124Thyroid hormones increasedFAERS: 2US FAERS
125Urinary IncontinenceFAERS: 2US FAERS
126Urine flow decreasedFAERS: 2US FAERS
127Uterine ProlapseFAERS: 2US FAERS
128Vulvovaginal rashFAERS: 2US FAERS
129VulvovaginitisFAERS: 2US FAERS
130White blood cell count decreasedFAERS: 2US FAERS
131Accidental underdoseFAERS: 1US FAERS
132Adnexa uteri painFAERS: 1US FAERS
133AgitationFAERS: 1US FAERS
134Allergic respiratory symptomFAERS: 1US FAERS
135AngerFAERS: 1US FAERS
136AngioedemaFAERS: 1US FAERS
137Anorectal discomfortFAERS: 1US FAERS
138ArthropathyFAERS: 1US FAERS
139AsthmaFAERS: 1US FAERS
140Atrophic vulvovaginitisFAERS: 1US FAERS
141Autonomic nervous system imbalanceFAERS: 1US FAERS
142Back disorderFAERS: 1US FAERS
143BlepharospasmFAERS: 1US FAERS
144Blood prolactin increasedFAERS: 1US FAERS
145Blood triglycerides increasedFAERS: 1US FAERS
146Bone density abnormalFAERS: 1US FAERS
147Capillary FragilityFAERS: 1US FAERS
148Cardiac discomfortFAERS: 1US FAERS
149ChokingFAERS: 1US FAERS
150Cold sweatFAERS: 1US FAERS
151ColitisFAERS: 1US FAERS
152Contraindicated drug prescribedFAERS: 1US FAERS
153Cortisol increasedFAERS: 1US FAERS
154CraniectomyFAERS: 1US FAERS
155CystFAERS: 1US FAERS
156DementiaFAERS: 1US FAERS
157DiscomfortFAERS: 1US FAERS
158Drug effective for unapproved indicationFAERS: 1US FAERS
159Drug screen positiveFAERS: 1US FAERS
160DysarthriaFAERS: 1US FAERS
161Endometrial adenocarcinomaFAERS: 1US FAERS
162EndometriosisFAERS: 1US FAERS
163ExcoriationFAERS: 1US FAERS
164Exposure via partnerFAERS: 1US FAERS
165Eye painFAERS: 1US FAERS
166Eyelid infectionFAERS: 1US FAERS
167Feeling jitteryFAERS: 1US FAERS
168Feeling of body temperature changeFAERS: 1US FAERS
169Gait inabilityFAERS: 1US FAERS
170Genital HerpesFAERS: 1US FAERS
171Genital burning sensationFAERS: 1US FAERS
172Genital rashFAERS: 1US FAERS
173HemiparesisFAERS: 1US FAERS
174HirsutismFAERS: 1US FAERS
175HydrometraFAERS: 1US FAERS
176HypersomniaFAERS: 1US FAERS
177Inadequate lubricationFAERS: 1US FAERS
178Inappropriate schedule of product administrationFAERS: 1US FAERS
179IncontinenceFAERS: 1US FAERS
180Incorrect dose administeredFAERS: 1US FAERS
181InflammationFAERS: 1US FAERS
182Initial insomniaFAERS: 1US FAERS
183Intracranial AneurysmFAERS: 1US FAERS
184Intraductal papilloma of breastFAERS: 1US FAERS
185Limb discomfortFAERS: 1US FAERS
186Medication monitoring errorFAERS: 1US FAERS
187Migraine with AuraFAERS: 1US FAERS
188Mouth swellingFAERS: 1US FAERS
189Musculoskeletal chest painFAERS: 1US FAERS
190Musculoskeletal discomfortFAERS: 1US FAERS
191Noninfective encephalitisFAERS: 1US FAERS
192OnychoclasisFAERS: 1US FAERS
193Orgasmic sensation decreasedFAERS: 1US FAERS
194OsteopeniaFAERS: 1US FAERS
195ParanoiaFAERS: 1US FAERS
196Pelvic discomfortFAERS: 1US FAERS
197Peripheral embolismFAERS: 1US FAERS
198Personality ChangeFAERS: 1US FAERS
199Portal Vein ThrombosisFAERS: 1US FAERS
200Post procedural complicationFAERS: 1US FAERS
201Premature MenopauseFAERS: 1US FAERS
202Premenstrual painFAERS: 1US FAERS
203Product use issueFAERS: 1US FAERS
204RosaceaFAERS: 1US FAERS
205ScreamingFAERS: 1US FAERS
206SepsisFAERS: 1US FAERS
207SinusitisFAERS: 1US FAERS
208Skin PapillomaFAERS: 1US FAERS
209Skin texture abnormalFAERS: 1US FAERS
210Skin tightnessFAERS: 1US FAERS
211Spontaneous ejaculationFAERS: 1US FAERS
212StomatitisFAERS: 1US FAERS
213Tardive DyskinesiaFAERS: 1US FAERS
214TensionFAERS: 1US FAERS
215ThrombophlebitisFAERS: 1US FAERS
216Thyroid hormones decreasedFAERS: 1US FAERS
217TinnitusFAERS: 1US FAERS
218Tongue discomfortFAERS: 1US FAERS
219Urinary RetentionFAERS: 1US FAERS
220Urinary tract discomfortFAERS: 1US FAERS
221Uterine spasmFAERS: 1US FAERS
222Vaginal lesionFAERS: 1US FAERS
223Viral upper respiratory tract infectionFAERS: 1US FAERS
224Weight decreasedFAERS: 1US FAERS
225Wrong drug administeredFAERS: 1US FAERS
226Embolic strokeSIDER
227Mammary Neoplasms, Experimental16153821CTD
228Osteoporosis, Postmenopausal16816926CTD
229Thromboembolic strokeSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.